Antibiotic chloramphenicol (CHL) binds with a moderate affinity at the peptidyl transferase center of the bacterial ribosome and inhibits peptide bond formation. As an approach for modifying and potentially improving properties of this inhibitor, we explored ribosome binding and inhibitory activity of a number of amino acid analogs of CHL. The L-histidyl analog binds to the ribosome with the affinity exceeding that of CHL by 10 fold. Several of the newly synthesized analogs were able to inhibit protein synthesis and exhibited the mode of action that was distinct from the action of CHL. However, the inhibitory properties of the semi-synthetic CHL analogs did not correlate with their affinity and in general, the amino acid analogs of CHL were less active inhibitors of translation in comparison with the original antibiotic. The X-ray crystal structures of the Thermus thermophilus 70S ribosome in complex with three semi-synthetic analogs showed that CHL derivatives bind at the peptidyl transferase center, where the aminoacyl moiety of the tested compounds established idiosyncratic interactions with rRNA. Although still fairly inefficient inhibitors of translation, the synthesized compounds represent promising chemical scaffolds that target the peptidyl transferase center of the ribosome and potentially are suitable for further exploration.
Introduction
Many antibiotics stop growth of pathogenic bacteria, and thereby cure infections, by selectively binding to the bacterial ribosomes and inhibiting protein synthesis. Antibiotics can interfere with translation by interacting with various functional centers of the ribosome and either locking of a particular conformation of the ribosome or hindering the binding of its ligands. The peptidyl transferase center (PTC), located in the large ribosomal subunit, is targeted by a particularly broad array of inhibitors belonging to several distinct chemical classes, such as phenicols, lincosamides, oxazolidinones, pleuromutilins, streptogramins A, and others [1] . From the oldest chloramphenicol (CHL) to the newest Food and Drug Administration-approved retapamulin, PTC-targeting drugs are known as excellent antibacterial agents.
Most of the PTC-targeting compounds inhibit protein synthesis by competing with the positioning of the amino acid side chain of the incoming aminoacyl-tRNA (aa-tRNA) in the A site [2] [3] [4] . CHL, a typical example from this family, inhibits translation in a wide range of Gram-positive and Gram-negative bacteria [5] . It binds to the A site of the PTC in a crevice formed by the bases of the conserved nucleotides U2504, A2451, and C2452 of the 23S rRNA and its nitrobenzyl ring forms a π-stacking interaction with the base of C2452 [6, 7] . The aromatic ring of the ribosome-bound CHL overlaps with the placement of the side chains of the incoming aa-tRNAs, thus efficiently preventing the aminoacyl moiety of aa-tRNA from properly accommodating into the PTC active site. CHL was originally viewed as a universal inhibitor of peptide bond formation [8] . However, this model has been recently revised because the newer data revealed CHL as a context-specific inhibitor of translation, whose activity depends on the nature of specific amino acids in the nascent chain and the identity of the residue entering the A site [9] .
While CHL does not act upon the eukaryotic cytoplasmic ribosome, it readily binds to the ribosomes of the mammalian mitochondria [10] [11] [12] [13] [14] . The interference with mitochondrial translation, which is the cause of the major side effects of CHL, significantly curbed the medical use of this drug in many countries [5, 15, 16] . Amending the CHL structure with the additional chemical entities that would form idiosyncratic interactions specifically with the bacterial ribosome could be one approach for the development of more selective inhibitors. In addition, the rapid spread of antibiotic resistance has significantly limited the medical utility of many available antibiotics, including the PTC-targeting drugs. One of the recently discovered but rapidly spreading resistance mechanisms operates via modification of the 23S rRNA nucleotide A2503, which is located in the binding site of several inhibitors. The rRNA methyltransferase Cfr adds a methyl group to the C8 position of the A2503 and renders bacteria resistant to a wide range of antibiotics targeting the catalytic center of the ribosome [17, 18] . The development of newer derivatives of the existing antibiotic platform, which could avoid a clash with the C8 methyl group of the Cfr-modified A2503, has proved to be a viable approach for overcoming such resistance [19] .
Previously, attempts were made to prepare peptide derivatives of CHL containing peptides of up to 10 amino acids long aiming to identify interactions between the peptide chain and the elements of the nascent peptide exit tunnel (NPET) [20, 21] . In the current study, with the goal of paving the way for development newer derivatives of CHL that would target the PTC, we have prepared several semi-synthetic analogs carrying various individual amino acids attached to the drug. Using competition-binding experiments, we investigated the affinities of the newly prepared compounds for their target and found that some of them show improved binding to the bacterial ribosome. We also showed that the mode of action of the newer analogs differs from the site-specific action of CHL. By solving the X-ray crystal structures of the Thermus thermophilus (Tth) 70S ribosome in complex with several CHL analogs, we observe specific interactions of the amino acid moiety with rRNA, thereby rationalizing the improved binding. Although the higher affinity of the derivatives to the vacant Escherichia coli ribosome does not directly translate into stronger inhibition of protein synthesis, the compounds described here could open new directions for improving the medical utility of amphenicol class of the ribosome inhibitors.
Results and Discussion

Synthesis of CAM derivatives
Chemical synthesis of CHL analogs carrying amino acid residues instead of dichloroacetic moiety is based on acylation of CHL amine (CAM), an inactive CHL derivative, with activated amino acids (Figs. 1 and S1) [22] . The overall synthesis scheme includes three steps: (i) acid hydrolysis of CHL to yield CAM [23] ; (ii) acylation of CAM by succinimide esters of amino acids with protected α-amino group and side-chain groups; and (iii) de-protection of the obtained CAM-derivatives to yield aminoacyl-CAM (AA-CAM) (Figs. 1 and S1). Using this approach, we have prepared CHL analogs aminoacylated with different amino acids, including the N-protected ones (Table 1) . Molecular weights and chemical structures of all synthesized CAM derivatives were confirmed by mass spectrometry and 1 H-and 13 C-NMR. Although few individual amino acid analogs of CHL have been studied previously [22, 24, 25] , this work represents the first systematic approach to synthesis and functional assessment of more than three dozens of various AA-CAMs.
AA-CAM compounds bind tightly to the bacterial ribosome
We used the competition-binding assay, exploiting BODIPY-labeled erythromycin (BODIPY-ERY) to assess the affinity of the synthesized compounds for the ribosome [26, 27] . While CHL binds in the A site of the PTC [6, 28] , ERY binds in the upper part of the NPET [7] but their binding sites sufficiently overlap so that even unmodified CHL and ERY compete for their binding to the ribosome [29] (Fig. S2) . The overlap of the AA-CAMs with ERY is expected to be even more pronounced. The apparent dissociation constant K Dapp of CHL obtained using competition with BODIPY-ERY (2.8 ± 0.5 μM) is consistent with the previously published data determined by direct [ 14 C]-CHL binding (2.3 μM [30] ). Using this approach, we found that many of the synthesized CAM derivatives exhibited considerable affinity for the ribosome (K Dapp in the low micromolar range) ( Table 1) . Interestingly, all of the AA-CAM derivatives carrying free α-amino groups bind to the ribosome with higher affinities than the corresponding compounds in which the α-amino group was modified by acetylation or formylation or protected by the Boc group ( Fig. S3 ; Table 1 ). This result suggests that the positive charge, the small size of the α-amino group, or both contribute to the efficient ribosome binding of AA-CAMs. Importantly, one AA-CAM variant, His-CAM, binds to the ribosome with a more than 10-fold higher affinity than CHL (His-CAM, K Dapp = 0.24 ± 0.06 μM) ( Fig. 2a ; Table 1 ).
AA-CAM compounds are less efficient inhibitors of translation than CHL and do not show the same context specificity To check whether the binding strength of AA-CAMs correlates with inhibition of translation, we tested their ability to interfere with in vitro protein synthesis. Addition of 30 μM CHL to the cell-free transcription-translation system based on the E. coli cell extract resulted in a near-complete inhibition of synthesis of firefly luciferase reporter (Fig. 2b) . Consistent with previously published (1) 0.24 ± 0.06 Ac-Arg-CAM (3a) 26±10 Lys-CAM (2) 1.6 ± 0.5 Ac-His-CAM (1a) 34±5 Arg-CAM (3) 3.2 ± 1.4 Ac-Lys-CAM (2a) 43±12 Ala-CAM (4) 5.3 ± 0.9 Ac-Ala-CAM (4a) 55±13 Gly-CAM (5) 5.7 ± 0.9 Ac-Gly-CAM (5a) 69±14 Gln-CAM (6) 6.3 ± 5.1 Ac-Phe-CAM (11a) 92 ± 22 Pro-CAM (7) 7.5 ± 1.6 Ac-Trp-CAM (10a) 106 ± 36 Tyr-CAM (8) 8.2 ± 1.5 Ac-Tyr-CAM (8a) 140 ± 50 Ser-CAM (9) 8.4 ± 2.4 Boc-His-CAM (1d) 19 ± 5 Trp-CAM (10) 12 ± 2 Boc-Gly-CAM (5d) 45 ± 8 Phe-CAM (11) 19 ± 8 Boc-Phe-CAM (11d) 160 ± 120 Val-CAM (12) 34 ± 8 Boc-Ala-CAM (4d) 170 ± 60 Leu-CAM (13) 36 ± 6 Boc-Pro-CAM (7d) 440 ± 230 Ile-CAM (14) 36 ± 10 f-Gly-CAM (5b) 4 5±6 Asn-CAM (15) 40 ± 26 D-His-CAM (1b) 2.9 ± 0.8
Numbers in the parenthesis correspond to the particular compound from the synthesis scheme shown in Fig. S1 . results, removal of the dichloroacetyl moiety from CHL results in nearly complete loss of its biological activity (Fig. 2b , CHL versus CAM) [23] , likely due to the loss of interactions of the dichloroacetic moiety with the ribosome [6] . However, similar to the previous studies employing peptide derivatives of CHL [5, 20, 31] , the inhibitory activity of CAM can be partially restored by incorporation of specific amino acids (Fig. 2b) , indicating that the contacts of the aminoacyl side chain of AA-CAMs with the ribosome may compensate for the interactions lost upon the removal of the dichloroacetic g r o u p . H o w e v e r , m o s t o f t h e t e s t e d AA-CAM-derivatives were less potent inhibitors of translation than CHL (Fig. 2b) . Even His-CAM, which exhibited higher than CHL affinity for the ribosome, reduced the yield of the functional luciferase by only 60%. Only the activity of β-Ala-CAM approached that of CHL, although this derivative demonstrated a twofold weaker binding to the ribosome compared to the parental compound. The modification of the α-amino group of AA-CAMs (with formyl, acetyl, or Boc groups) leads to a nearly complete loss of their inhibitory potency (Fig. 2b) . The inability of most of the AA-CAM compounds to efficiently inhibit translation could be potentially explained by the susceptibility of AA-CAMs to the action of peptidases present in the bacterial extract-based cell-free translation system. Therefore, we re-tested the inhibitory activity of some of the compounds in the PURE cell-free translation system reconstituted from purified components and thus lacking peptidases [32] . All of the tested compounds exhibited inhibitory activity in the PURE system ( Fig. 2c) , suggesting that the stability of our compounds is unlikely to be the key issue. Although the overall inhibition of translation by AA-CAM derivatives in the PURE system has improved compared to their effect upon translation in the cell extract, it still did not reach the level of inhibition elicited by the CHL, suggesting that the equilibrium binding affinities of the tested inhibitors to a vacant ribosome might not adequately reflect the interactions of these compounds with the translating ribosome carrying mRNAs, tRNAs, and nascent peptide chain. Several peptide derivatives of CAM have been prepared and tested previously in the binding and inhibition assays [20, 31] . Similar to our findings, those derivatives were found to be poor inhibitors of translation. The inhibition of protein synthesis by CHL depends on the amino acid sequence of the nascent peptide and the identity of the aa-tRNA, with the most efficient arrests occurring after alanine (and to a lesser extent after serine or threonine) that appear at the penultimate position of the nascent chain [9] . To test whether the specificity of action of AA-CAM compounds matches that of CHL, we used primer extension inhibition assay (toe-printing) to check whether the derivatives that exhibited inhibitory activity in the PURE system (Fig. 2d) would arrest the ribosome at the same codon(s) where translation is arrested by CHL. In these experiments, we used a short synthetic open reading frame (ORF) encoding the peptide MFKAFKNIIRTRTL, where CHL efficiently arrests the ribosome at the fifth codon after the MFKAF peptide has been synthesized (Fig. 2d , lanes 3 and 9, green arrowheads). Some translation reactions were additionally supplemented with mupirocin, an inhibitor of isoleucyl-tRNA synthetase. The depletion of isoleucyl-tRNA efficiently traps the ribosomes at the seventh codon of the ORF if they were not arrested at any of the prior codons by the action of the ribosome inhibitor (Fig. 2d, lanes 1-6 , blue arrowheads) helping to evaluate the efficiency of the antibiotic-dependent arrest [33] . Only a small fraction of ribosomes pre-incubated with CHL was able to reach the "trap" codon (Fig. 2d, lane 3) because most of the translation complexes were arrested at the fifth codon. In contrast, the intensity of the trap-codon band was only slightly diminished in samples supplemented with AA-CAM analogs and no strong arrest was observed at the fifth codon (Fig. 2d, lanes 4-6) . This was in spite of the fact that the concentrations of AA-CAM compounds in the toe-printing experiments (100 μM) were several-fold higher than those used in the cell-free translation experiments (Fig. 2b, c) , where the same derivatives were able to inhibit expression of the luciferase reporter with a considerable activity. We noted, however, that the toe-print bands corresponding to the initiating ribosome were slightly enhanced compared to the no-drug (+/− mupirocin) control (Fig. 2d, lanes 2 and 8 versus lanes 4-6 and 10-12 , respectively, black arrowheads), indicating that AA-CAM analogs weakly interfered with translation initiation, likely by inhibiting the formation of the first peptide bond. We concluded that AA-CAM derivatives do not show the same site specificity of action as the parent compound CHL, apparently due to idiosyncratic interactions of the aminoacyl moieties of AA-CAMs with the ribosome.
Aminoacyl moieties of AA-CAMs mediate specific interactions with the ribosome
To unambiguously determine the mode of binding of AA-CAM derivatives to the ribosome, we crystallized Tth 70S ribosomes in the presence of mRNA, deacylated A-, P-, and E-site tRNAs, and His-CAM and solved the structure of the complex at 2.8-Å resolution. However, the other complexes prepared in this way did not diffract sufficiently well. Therefore, we amended our crystallization approach by using ribosome complexed with the protein Y (PY) as a tool to obtain structures of higher resolution [34, 35] . This approach is based on our recent finding that binding of PY to a vacant 70S ribosome stabilizes it by locking the head of the 30S subunit in an unrotated state, which leads to a better diffraction [34, 35] . Since PY binds in the mRNA channel on the 30S subunit far away from the CHL binding site in the PTC of the 50S subunit, it precludes the presence of mRNA or A-and P-tRNAs [34] . However, this does not interfere with the binding of AA-CAMs. Using this approach, we were able to solve two additional structures of D-His-CAM and Lys-CAM in complex with the PY-bound 70S ribosome at 2.7-and 2.6-Å resolutions, respectively (Table S1 ). An unbiased difference Fourier map, calculated using the amplitudes from the crystals and phases derived from a model of the ribosome without the bound compound, revealed positive electron density resembling characteristic features of each of the compounds (Fig. 3) . A single binding site for each of the AA-CAMs is observed in the ribosome within the PTC of the large ribosomal subunit (Fig. 4) .
The binding position of the amphenicol parts of AA-CAMs is identical to those observed previously for parent CHL in the Tth [7] or Eco [28] ribosomes in the absence of mRNA and tRNAs (Fig. S4) . The amino acid moieties of AA-CAMs are oriented t o w a r d t h e N P E T a n d e x h i b i t u n i q u e compound-specific interactions at the PTC (Figs. 4  and 5) . Histidine side chain of His-CAM forms tilted edge-to-face π-stacking with the nucleobase of U2506 (Figs. 4d and 5a ). In addition, the α-amino group of His-CAM forms hydrogen bond (H-bond) via a water molecule with the phosphate of nucleotide G2505 (Fig. 5a ). These additional interactions of the aminoacyl moiety likely account for its increased affinity to the ribosome compared to CHL. Contrary to His-CAM and consistent with its significantly lower affinity, α-amino group of the D-His-CAM stereoisomer does not form the water-mediated H-bond with G2505 (Fig. 5b) . Surprisingly, the orientation of the amino acid side chain of L-Lys-CAM is similar to that of D-His-CAM (Fig. 5c) . The lysine moiety of Lys-CAM extends toward the wall of the NPET and, similar to D-His-CAM, forms a single H-bond with the nucleobase of A2059 explaining why their binding is less tight in comparison with His-CAM.
In the structure of the ribosome/His-CAM complex, the oxygens of the nitro group in the CAM moiety form H-bonds with the A76 ribose hydroxyls of deacylated A-and P-site tRNAs (Fig. 4c) . It is unclear whether such interactions are possible in the translating ribosome when the P-site tRNA is attached to the aminoacyl or peptidyl groups. Nevertheless, our structures clearly demonstrate that amphenicol part of the AA-CAMs is capable of anchoring the derivatives in the PTC active site directing the attached amino acids in the direction corresponding to the growing peptide chain.
Resistance to many peptidyl transferase inhibitors (including CHL) can be conferred by Cfr, a methyltransferase that methylates A2503 of the 23S rRNA at the C8 atom [18] . The methyl group added to A2503 by Cfr would invade the CHL binding pocket if the placement of the modified A2503 remains unchanged (Fig. 6a) . In silico modeling shows, however, that the ribosome-bound His-CAM whose placement in the PTC is somewhat shifted relative to CHL, would avoid the collision with C8-methyl group of A2503 (Fig. 6b) , suggesting that this compound could retain certain activity against the Cfr-modified ribosome. Likewise, the resistance to CHL conferred by the mutation of A2503 to G [36] , is likely to be less pronounced in the case of His-CAM due to a more remote position of the amino acid side chain of His-CAM relative to the site of the mutation. Therefore, the structure of the ribosome with the AA-CAM derivatives suggests that some of the amino acid analogs of CHL could be less susceptible to the action of specific resistance mechanisms. Further experiments would be required to check whether any of the synthesized CHL analogs are active against ribosomes rendered resistant to CHL.
The structure of PTC is highly conserved among evolutionary distant ribosomes, including the ribosomes of mitochondria, which are known to be targeted by CHL [10] [11] [12] [13] [14] . However, even minor variations in the placement of the nucleotides directly interacting with the drug, which could be influenced by the less conserved second-shell nucleotides, could account for the selectivity of the antibiotics that bind in the PTC active site as well as for the differential effect of these drugs upon ribosomes from different species. Because the compounds examined in our study have fairly low activity against the bacterial ribosome, we have not pursued studies of their effects upon mitochondrial translation. However, we believe that adding an amino acid or its analog to the drug core could potentially influence the spectrum of action of this class of the ribosomal antibiotics opening a possibility of making them more selective inhibitors of bacterial translation.
Conclusions
The goal of the current study was to develop amino acid analogs of CHL as an approach for exploring this line of derivatives as new inhibitors of translation. We used organic synthesis to generate a diverse set of amino acid analogs of native CHL and examined their ribosome binding and inhibitory properties. We have demonstrated that His-CAM, a histidine analog of CHL, exhibits 10 times higher affinity for the bacterial ribosome as compared to CHL. We have noted, however, that the inhibitory properties of the semi-synthetic CHL analogs do not correlate with their binding affinities to the vacant ribosomes and the compounds with high affinities, such as His-CAM, inhibit translation less efficiently than CHL, while compounds with low affinities, such as β-Ala-CAM, demonstrated inhibitory properties similar to those of the parental drug. Our crystal structures show that amino acid analogs of CHL establish compound-specific interactions with the nucleotides of the 23S rRNA at the PTC and orient the amino acid moiety in the direction of the upper part of the peptide exit tunnel. The idiosyncratic interactions with the ribosome of the amino acid residue attached to the CHL core open the possibility of increasing the selectivity of this class of antibiotics and possibly diminish their side effects mediated by the action upon mitochondrial translation. Moreover, the possibility that some of the amino acid derivatives of CHL might act upon drug-resistant ribosome makes them attractive compounds for further exploration by medicinal chemists, and we expect that our findings, including the structure of the AA-CAMribosome complexes described here, will serve as a starting point for such studies.
Materials and Methods
Reagents
Various amino acid derivatives used in chemical synthesis (Supplementary Methods) were from Fluka or Reanal; CHL was from Sigma; succinimide ester of BODIPY was from Invitrogen; and N-hydroxysuccinimide, N,N′-dicyclohexylcarbodiimide, and DMAP were from Merck. BODIPY-ERY was synthesized as described previously [37] .
Chemical synthesis of AA-CAM derivatives
The general scheme for the synthesis of AA-CAM derivatives is shown in Fig. S1 and the details of chemical synthesis are provided in the Supplementary Methods section. CAM [(1R,2R)-2-amino-1-(4--nitrophenyl)propane-1,3-diol)] was prepared as described previously [23] . Amino acids with protected α-and side-chain amino groups were activated by reaction with N-hydroxysuccinimide in the presence of N,N′-dicyclohexylcarbodiimide at 0°C. The resulting succinimide-reactive esters were used for the acylation of CAM in the presence of diisopropylethylamine as a base at room temperature. Subsequent deprotection was achieved by treatment of the obtained amino-acid CAM derivatives with trifluoroacetic acid and appropriate scavengers. Synthesized AA-CAM derivatives were purified by column chromatography on silica gel using suitable systems of solvents. For generating N-acetylated variants of AA-CAM, additional acetylation was performed by reacting the unprotected AA-CAM derivatives with the N-acetylsuccinimide. Purity and chemical structures of obtained compounds were confirmed by HPLC, LC-MS, and NMR spectroscopy (see Supplementary Methods).
In vitro binding assay
Binding affinities of CAM-derivatives to E. coli ribosomes was analyzed by competition-binding assay using fluorescently labeled BODIPY-ERY as described before [26, 27, 37] . BODIPY-ERY (4 nM) was incubated with ribosomes (25 nM) for 30 min at 25°C in the buffer containing 20 mM Hepes-KOH (pH 7.5), 50 mM NH 4 Cl, 10 mM Mg(CH 3 COO) 2 , and 0.05% Tween-20. The solution of CAM derivatives in a range of concentrations from 0.1 μM to 1 mM was added to the formed complex. The mixture was incubated for 2 h until equilibrium was reached and the values of fluorescence polarization were measured.
In vitro translation
Inhibition of firefly luciferase synthesis in cell-free translation systems by AA-CAMs was tested as described previously [38] . Briefly, the in vitro transcribed firefly luciferase mRNA was translated using either PURExpress system (New England Biolabs) or E. coli S30 extract prepared according to Svetlov et al. [39] . Reactions were programmed with 100 ng mRNA and were carried out in 5 μL aliquots at 37°C for 30 min. The AA-CAMs were added to 30 μM final concentration. The activity of in vitro synthesized luciferase was assessed using 5 μL of the substrate from the Steady-Glo Luciferase Assay System (Promega).
Toe-printing analysis of compound-induced ribosome stalling
Toe-printing experiments were performed in the PURExpress cell-free translation system (New England Biolabs) following our published protocols [40, 41] . The synthetic template encoding the amino acid sequence MFKAFKNIIRTRTL was initially generated by PCR reaction using a combination of five primers: 2 μM T7 (ATTAATACGACTCACTA TAGGG), 2 μM NV1 (GGTTATAATGAATTTTGCT TATTAAC), and 0.2 μM of each of the following: Fv (AATACGACTCACTATAGGGCAACCTAAAACT TACACACGCCCCGGTAAGGAAATAAAAAT), inner (GCCCCGGTAAGGAAATAAAAATGTTC A AA G C A TT C AA A A AC A TC A T AC G T A CT C G TACTC), and Rev. (GGTTATAATGAATTTTGCTT ATTAACCTTGCCTGCGCTTAAAGAGTACGAG TACGTATGATGT) as described in Ref. [42] . The product was cloned into the pUC18 plasmid cut with the SmaI restriction enzyme and the resulting pUCMFKAFK plasmid was verified by capillary sequencing. For the toe-printing reaction, the template was PCR-amplified from the pUCMFKAFK plasmid using T7 and NV1 primers. When needed, the other antibiotics (retapamulin, CHL, and AA-CAM analogs) were present in the reaction at the final concentration of 100 μM. In addition, all the toe-printing reactions were supplemented with the Ile-RS inhibitor mupirocin (final concentration 50 μM), which caused translating ribosomes to pause when an isoleucine codon was encountered.
Crystallographic structure determination
Ribosome complexes with mRNA and tRNAs or with PY were formed as described previously [35] .
CAM derivatives were added to the pre-formed ribosome complexes to a final concentration of 250 μM prior to crystallization. All Tth 70S ribosome complexes were formed in the buffer containing 5 mM Hepes-KOH (pH 7.6), 50 mM KCl, 10 mM NH 4 Cl, and 10 mM Mg(CH 3 COO) 2 , and then crystallized in the buffer containing 100 mM Tris-HCl (pH 7.6), 2.9% (w/v) polyethylene glycol 20K, 7%-12% (v/v) methyl-2,4-pentanediol, 100-200 mM arginine, 0.5 mM β-mercaptoethanol. Crystals were grown by the vapor diffusion method in sitting drops at 19°C and stabilized as described previously [35] , with the corresponding CAM-derivatives being added to the stabilization buffers (100 μM each). Diffraction data were collected using beamlines 24ID-C and 24ID-E at the Advanced Photon Source (Argonne, IL). All crystals belonged to the primitive orthorhombic space group P2 1 2 1 2 1 with approximate unit cell dimensions of 210 Å × 450 Å × 620 Å and contained two copies of the 70S ribosome per asymmetric unit. Each structure was solved by molecular replacement using PHASER from the CCP4 program suite [43] . The search model was generated from the previously published structures of Tth 70S ribosome with bound mRNA and tRNAs (PDB entry 4Y4P from Ref. [35] ) or with PY (PDB entry 4Y4O from [35] ). The initial molecular replacement solutions were refined by rigid body refinement with the ribosome split into multiple domains, followed by positional and individual B-factor refinement. The final models of the 70S ribosome in complex with His-CAM and mRNA/tRNAs, or in complex with D-His-CAM/Lys-CAM and PY were generated by multiple rounds of model building in COOT [44] , followed by refinement in PHENIX [45] . The statistics of data collection and refinement are compiled in Table S1 .
Accession Numbers
Coordinates and structure factors were deposited in the RCSB Protein Data Bank with accession code 6CFJ for the T. thermophilus 70S ribosome in complex with His-CAM, mRNA, A-, P-and E-site tRNAs; 6CFK for the T. thermophilus 70S ribosome in complex with D-His-CAM and protein Y; and 6CFL for the T. thermophilus 70S ribosome in complex with Lys-CAM and protein Y.
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